Hexvix (Hexaminolevulinate)

Hexvix is indicated for the optical detection of malignant lesions in the bladder during cystoscopic procedures.

• Identification of non‑muscle‑invasive bladder cancer (NMIBC) lesions, including papillary tumors.
• Visualization of carcinoma in situ (CIS) that may be flat or difficult to see under white light.
• Adjunct to standard white‑light cystoscopy to improve lesion detection rates.
• Guidance for targeted biopsy or resection of suspicious areas.
• Assessment of treatment response in surveillance cystoscopies (optional).
• Facilitation of intra‑operative decision‑making regarding the extent of transurethral resection.

• Hexvix contains hexaminolevulinate, a prodrug that preferentially accumulates in malignant urothelial cells. Inside these cells, enzymatic conversion yields protoporphyrin IX, a fluorescent porphyrin. When the bladder is illuminated with blue light (approximately 405 nm), protoporphyrin IX emits red‑violet fluorescence, highlighting cancerous tissue while surrounding normal urothelium remains non‑fluorescent. This selective fluorescence enables clinicians to differentiate malignant lesions during cystoscopy in real time.

Adverse reactions reported with intravesical Hexvix are generally related to the local administration and the photosensitizing properties of the agent.

Common

• Bladder discomfort or urgency during or shortly after instillation.
• Mild hematuria or blood‑tinged urine.
• Transient dysuria (painful urination).
• Low‑grade fever or chills.
• Nausea or mild headache.
• Transient mild pelvic pain.
• Temporary increase in urinary frequency.

Serious

• Severe allergic reaction, including anaphylaxis.
• Acute urinary retention requiring catheterization.
• Persistent bladder inflammation (cystitis) with significant pain.
• Photosensitivity reactions affecting skin exposed to strong light after the procedure.
• Severe bladder spasm causing acute pain.
• Persistent systemic photosensitivity lasting more than 48 hours.
• Renal impairment secondary to obstructive retention.

When using Hexvix, clinicians should observe specific precautions to minimize risks and ensure accurate diagnostic results.

• Ensure complete bladder emptying before instillation to promote uniform distribution of the solution.
• Use the recommended concentration (85 mg/50 mL) and avoid dilution or concentration changes.
• Perform the procedure under blue‑light illumination only after the recommended incubation period (typically 60 minutes).
• Monitor patients for signs of allergic reaction during and after administration.
• Advise patients to avoid direct exposure to strong light sources for 24 hours post‑procedure.
• Do not use in patients with known hypersensitivity to porphyrins or similar photosensitizers.
• Pregnancy and lactation status should be evaluated, as safety data are limited.

Hexvix may interact with other agents that affect photosensitivity or urinary dynamics, requiring careful management.

Avoid

• Concurrent use of systemic photosensitizing drugs (e.g., porfimer sodium, aminolevulinic acid) that could amplify fluorescence.
• Exposure to intense ultraviolet or bright light sources during the 24‑hour post‑procedure window.
• Intravesical administration of other chemotherapeutic agents in the same session without proper flushing.

Use with caution

• Anticoagulants or antiplatelet therapy, as minor hematuria may be more pronounced.
• Agents that alter bladder wall permeability (e.g., dimethyl sulfoxide) which could affect drug uptake.
• Immunosuppressive medications, given the potential for altered inflammatory response.